Understand your drug better and increase success rates in early clinical development

Immuneed helps innovative biotechs advance their preclinical projects by providing a better understanding of their drug candidates. We are experts in immunology and pharmaceutical development and have experience working with a broad range of biotherapeutics. Immuneed offers services ranging from selecting the right drug candidate to evaluating infusion risks. Our expertise paired with our unique model of fresh, circulating human blood enables us to capture a breadth of the immune response not possible elsewhere. Immuneed's loop model is applicable during drug discovery and development – from screening of drug candidates to early clinical development. All our solutions are flexible and we tailor study design and project to address your specific needs

 

 

Contact Us!

Are you interested in our services to assess toxicity and/or efficacy of your drug candidate?

Get in touch to find out how we can help you!

I'm interested in






In order for us to get in touch with you we must store some of your data on our servers. Checking the 'I consent' box indicates that you have read our privacy policy which outlines how we process, protect and manage your data, and that you consent to us storing it in accordance with this policy.

I consent

NEWS

Meet us in Stockholm, Sep 2 for a 3-hour seminar on how tailored preclinical testing adds value to early clinical trials. - What factors impact R&D efficiency and overall success for a small- or medium-sized biotech company? The Center for Medicine Research International (CMR) reported in its Pharmaceutical R&D Factbook 2014 an average success rate of 4.9 % from first toxicity dose to market approval. So what is the reason for the high attrition rate?  The reasons are …
What’s lurking in that high background? - Uncover the potential safety risks of your drug candidate. Annually, the European pharma industry invests more than € 35 000 million to identify and develop new drugs, about 22% of which is spent on screening assays and toxicity testing. Of the 5000 compounds that enter pre-clinical testing, only five make it to the clinical phase. …
We’ll be at CIMT on May 21-23, 2019 - We’ll be attending CIMT May 21-23, 2019. Meet up with our COO Justyna and Head of Research Erika at booth #10. Poster Abstract #56 on Tuesday, May 21 at 15.00-17.00. Presentation on Thursday, May 23 at 12.00: “Immunotoxicity assessment in a loop with circulating human blood”. See you there!